Incyte (INCY)
(Delayed Data from NSDQ)
$64.14 USD
+1.12 (1.78%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $64.15 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Product revenues
- 3,165.17
- 2,746.90
- 2,322.01
- 2,068.74
- 1,774.92
- Revenue - Line of Business (LOBR)
- Revenues: Product royalty revenues
- 523.48
- 482.74
- 569.26
- 392.97
- 306.34
- Revenue - Line of Business (LOBR)
- Milestone and contract revenues
- 7.00
- 165.00
- 95.00
- 205.00
- 77.50
- Revenue - Line of Business (LOBR)
- Net product revenues: Jakafi
- 2,593.73
- 2,409.23
- 2,134.51
- 1,937.85
- 1,684.97
- Revenue - Line of Business (LOBR)
- Net product revenues: Iclusig
- 111.62
- 105.84
- 109.40
- 105.01
- 89.95
- Revenue - Line of Business (LOBR)
- Net product revenues: Pemazyre
- 83.64
- 83.45
- 68.53
- 25.88
- --
- Revenue - Line of Business (LOBR)
- Net product revenues: Minjuvi
- 37.06
- 19.65
- 4.91
- --
- --
- Revenue - Line of Business (LOBR)
- Net product revenues: Opzelura
- 337.86
- 128.74
- 4.67
- --
- --
- Revenue - Line of Business (LOBR)
- Royalty revenues: Jakavi
- 367.58
- 331.58
- 337.99
- 277.90
- 225.91
- Revenue - Line of Business (LOBR)
- Royalty revenues: Olumiant
- 136.14
- 134.55
- 220.88
- 110.92
- 80.42
- Revenue - Line of Business (LOBR)
- Royalty revenues: Tabrecta
- 17.79
- 15.41
- 10.39
- 4.14
- --